# Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes

> **NCT07229534** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Dong-A ST Co., Ltd.** · enrollment: 238 (estimated)

## Conditions studied

- Diabete Mellitus

## Interventions

- **DRUG:** DA-5218
- **DRUG:** DA-5218-C

## Key facts

- **NCT ID:** NCT07229534
- **Lead sponsor:** Dong-A ST Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 238 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07229534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07229534, "Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07229534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*